Vericel reported 1Q24 orthopedic sales of $40.2 million, up 17.5% compared to the first quarter of 2023.
Despite the seasonally slower first quarter, the company recorded its second-best MACI quarter ever, behind only the fourth quarter of 2023.
MACI’s expanding surgeon base and growing number of biopsies drove the product’s momentum in the first quarter. Vericel remains on track to launch MACI Arthro in the third quarter of 2024. The launch will eventually expand Vericel’s surgeon base from 5,000 to 7,000 and provide an important growth vector in the coming years.
For 2024, the company expects total sales between $238 million and $242 million, representing growth between 20% and 23%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
1Q24
1Q23
$ Chg
% Chg
Sports Medicine
$40.2
$34.2
$6.0
17.5%
Company Earnings
Amt
% of Sales
Sales
$51.3
Cost of Sales
$15.9
31.1%
General and Admin
$34.4
67.1%
R & D
$6.4
12.5%
Other
($1.6)
(3.1%)
Net Earnings
($3.9)
(7.5%)
Vericel reported 1Q24 orthopedic sales of $40.2 million, up 17.5% compared to the first quarter of 2023.
Despite the seasonally slower first quarter, the company recorded its second-best MACI quarter ever, behind only the fourth quarter of 2023.
MACI's expanding surgeon base and growing number of biopsies drove the product's momentum in...
Vericel reported 1Q24 orthopedic sales of $40.2 million, up 17.5% compared to the first quarter of 2023.
Despite the seasonally slower first quarter, the company recorded its second-best MACI quarter ever, behind only the fourth quarter of 2023.
MACI’s expanding surgeon base and growing number of biopsies drove the product’s momentum in the first quarter. Vericel remains on track to launch MACI Arthro in the third quarter of 2024. The launch will eventually expand Vericel’s surgeon base from 5,000 to 7,000 and provide an important growth vector in the coming years.
For 2024, the company expects total sales between $238 million and $242 million, representing growth between 20% and 23%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
1Q24
1Q23
$ Chg
% Chg
Sports Medicine
$40.2
$34.2
$6.0
17.5%
Company Earnings
Amt
% of Sales
Sales
$51.3
Cost of Sales
$15.9
31.1%
General and Admin
$34.4
67.1%
R & D
$6.4
12.5%
Other
($1.6)
(3.1%)
Net Earnings
($3.9)
(7.5%)
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
